R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
Ivy X. Chen,Kathleen Newcomer,Kristen E. Pauken,Kristen E. Pauken,Vikram R. Juneja,Vikram R. Juneja,Kamila Naxerova,Michelle W. Wu,Matthias Pinter,Debattama R. Sen,Meromit Singer,Meromit Singer,Arlene H. Sharpe,Arlene H. Sharpe,Arlene H. Sharpe,Rakesh K. Jain +15 more
TL;DR: The resection and response tumor model can be used to identify response and resistance biomarkers to ICB therapy and guide the use of combination therapy to further boost the antitumor efficacy of ICB.
Journal ArticleDOI
Executive function deficits in children with attention-deficit/ hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study
Atilla Turgay,Lawrence D. Ginsberg,Elias H. Sarkis,Rakesh K. Jain,Ben Adeyi,Joseph Gao,Bryan Dirks,Thomas Babcock,Brian Scheckner,Cynthia Richards,Robert Lasser,Robert L. Findling +11 more
TL;DR: Improvements were demonstrated in EF behaviors and ADHD symptoms with LDX and LDX safety profile was consistent with long-acting stimulant use.
Journal ArticleDOI
Description of a novel indole-oxidizing bacterium Pseudomonas indoloxydans sp. nov., isolated from a pesticide-contaminated site.
TL;DR: On the basis of differential phenotypic characteristics and genotypic distinctiveness, strain IPL-1(T), capable of oxidizing indole was isolated from a lindane-contaminated site and subjected to a polyphasic taxonomic study, should be classified within the genus Pseudomonas as a novel species, for which the name Pseudoms indoloxydans is proposed.
Journal ArticleDOI
Vascular diseases await translation of blood vessels engineered from stem cells
TL;DR: Current developments in the generation of vascular progenitor cells from hiPSCs and the assessment of their functional capacity in vivo are discussed, opportunities and challenges for the clinical translation of engineered vascular tissue, and modeling of vascular diseases using hiPSC-derived vascular progentitor cells are discussed.
Journal ArticleDOI
Effect of hemodilution and resuscitation on tumor interstitial fluid pressure, blood flow, and oxygenation
TL;DR: Mild hemorrhage can significantly lower TIFP without a reduction in TBF and pO2 without a lowering of tumor venous resistance, common to saline blood restitution and volume top-load with Dextran 70.